Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Climate change: the world’s greatest challenge

Three Gates Cambridge alumnae took part in the first of a series of online panels to celebrate the scholarship programme’s 20th anniversary. The panel discussion, Climate change: the world’s greatest challenge, took place on the day that the Gates Cambridge Class of 2021 was officially announced. The panel was introduced and hosted by Professor Stephen […]

Class of 2021 announced

The Gates Cambridge Class of 2021 made up of 74 outstanding new scholars has been officially announced. The Gates Cambridge scholarship programme, which this year celebrates its 20th anniversary, is the University of Cambridge’s leading international postgraduate scholarship programme. It was established through a US$210 million donation to the University of Cambridge from the Bill […]

Serotonin and its role in emotional responses

Two new studies which shed light on the role of serotonin in emotional responses have been published in leading journals. Jonathan Kanen [2015] is lead author of both. The first is published in Translational Psychiatry and looked at the influence of the neurotransmitter serotonin on emotional reactions to social conflict. The study involved volunteers drawing […]

Scholar wins NASA Fellowship

A Gates Cambridge Scholar has won a prestigious NASA Fellowship to continue his studies on exoplanets. Luis Welbanks has been awarded a NASA Hubble Fellowship and will begin his programme in the autumn at Arizona State University. The Fellowship programme “enables outstanding postdoctoral scientists to pursue independent research in any area of NASA Astrophysics, using […]